GPP
ATYR

Great Point Partners’s aTyr Pharma ATYR Stock Holding History

Great Point Partners’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-3,565
Closed -$197K – 41
2016
Q1 		$197K Buy
+3,565
New +$271K 0.07% 33

Other funds holding ATYR

RCM
Riverhead Capital Management Wilmington, Delaware $2.71B AUM 2.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Great Point Partners's ATYR Position: Q2 2016 in Review

Great Point Partners sold out of aTyr Pharma (ATYR) in Q2 2016, closing a stake of 3,565 shares — an estimated $197K sold.

Great Point Partners first reported a position in ATYR in Q1 2016 and held it in 1 quarter. The position peaked at $197K in Q1 2016. 49 funds tracked by Wall St. Rank hold ATYR as of Q2 2016.

  • Great Point Partners reported no remaining aTyr Pharma position as of Q2 2016 after selling out during the quarter.
  • Great Point Partners sold 3,565 aTyr Pharma shares in Q2 2016, an estimated $197K.
  • Great Point Partners first reported a position in aTyr Pharma in Q1 2016 and held it in 1 quarter.
  • Great Point Partners's aTyr Pharma position peaked at $197K in Q1 2016.
  • 49 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2016.

Based on Great Point Partners's 13F filing for Q2 2016, filed 15 Aug 2016.